Skip to main content

Table 1 Baseline characteristics of patients [numbers (n) and percentages (%)]

From: Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020

 

N = 655

Age (years), n (%)

 18–29

81 (12)

 30–39

185 (28)

 40–49

207 (32)

 50–59

147 (22)

 ≥ 60

35 (5)

 Mean (SD)

43 (11)

Gender, n (%)

 Male

462 (71)

 Female

193 (29)

Highest educational level, n (%)

 Not completed primary school

40 (6)

 Completed primary school (9 years)

286 (44)

 Completed high school (12 years)

260 (40)

 ≤ 3 years of college or university

57 (9)

 > 3 years of college or university

12 (2)

Receiving OAT, n (%)

542 (83)

OAT opioid, n (%):

 Methadone

212 (39)

 Buprenorphinea

323 (60)

 Long-acting morphine sulfate

7 (1)

Housing situation the past 30 days, n (%)

 Owned or rented housing

518 (79)

 Temporary residence (homeless shelter, with family or friends)

156 (24)

 Living on street

27 (4)

 Prison

7 (1)

 Other

27 (4)

Ever injected substances, n (%)

573 (94)

Injected substances the past 30 days, n (%)

257 (42)

  1. OAT opioid agonist therapy, SD standard deviation
  2. a“Buprenorphine” includes buprenorphine, buprenorphine-naloxone, and buprenorphine depot